Welcome to our dedicated page for AZYO news (Ticker: AZYO), a resource for investors and traders seeking the latest updates and insights on AZYO stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect AZYO's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of AZYO's position in the market.
Aziyo Biologics (Nasdaq: AZYO) will participate in the upcoming Piper Virtual Healthcare Conference from December 1-3, 2020. The company specializes in regenerative medicine, focusing on enhancing surgical outcomes for patients with implantable medical devices. A fireside chat will be available the week of November 23, 2020, accessible through the Investors section of their website. Founded in 2015, Aziyo has developed a portfolio of products for cardiovascular, orthopedic, and reconstructive specialties.
Aziyo Biologics, Inc. and Surgalign Holdings, Inc. have expanded their distribution agreement, allowing Surgalign to distribute the new ViBone® Moldable product in the U.S. This innovative bone graft solution aims to improve spinal fusion surgeries, joining other advanced orthobiologic solutions currently offered by Surgalign. The orthopedic and spinal repair market presents a significant opportunity, valued at approximately $2 billion annually, with 1.5 million procedures using biologic materials. The partnership is positioned to enhance patient outcomes and surgeon experiences.
Aziyo Biologics has secured a group purchasing agreement with Premier Inc. for its CanGaroo Envelope, effective December 1, 2020. This FDA-cleared extracellular matrix (ECM) product is intended for cardiac implantable electronic devices (CIED) and aims to mitigate complications associated with such devices. CEO Ron Lloyd expressed enthusiasm about this recognition and the opportunity to enhance patient outcomes by making CanGaroo available to Premier's extensive network of healthcare providers.
Aziyo Biologics, a regenerative medicine company, plans to release its third quarter earnings results on November 19, 2020, after market close. A conference call will follow at 4:30 p.m. Eastern Time. Investors can access the call via phone or through a live webcast on the company's website. Aziyo focuses on developing differentiated medical products that improve surgical outcomes, particularly for patients with implantable devices. Since its inception in 2015, the company has built a portfolio for cardiovascular, orthopedic, and reconstructive applications.
Aziyo Biologics, Inc. (Nasdaq: AZYO) has priced its initial public offering at $17.00 per share, offering a total of 2,941,176 shares of common stock. This includes 2,205,882 shares of Class A and 735,294 shares of Class B common stock. The IPO aims to raise gross proceeds of $50 million, expected to close on October 13, 2020. Underwriters have a 30-day option to purchase an additional 441,176 shares. Trading under the ticker symbol AZYO will commence on October 8, 2020, with Piper Sandler and Cowen acting as joint book-running managers.
Aziyo Biologics has announced that Maybelle Jordan and Brigid Makes have joined its board of directors, enhancing expertise in biologics and medical devices. Jordan brings over 17 years of experience with Biomerix, while Makes has a strong background in finance and management from various medical firms. CEO Ron Lloyd expressed confidence that their contributions will strengthen the company’s product portfolio and customer relationships. Aziyo focuses on regenerative medicine, particularly for patients using implantable medical devices, and aims to improve surgical outcomes.